These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2473114)

  • 21. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).
    Kazatchkine MD; Fearon DT
    Immunodefic Rev; 1990; 2(1):17-41. PubMed ID: 2164822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
    Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
    J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.
    Molina H; Kinoshita T; Inoue K; Carel JC; Holers VM
    J Immunol; 1990 Nov; 145(9):2974-83. PubMed ID: 2145366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.
    Rayhel EJ; Dehoff MH; Holers VM
    J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
    Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
    Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
    Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
    J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
    Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
    Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
    Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
    Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
    Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
    J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines.
    Kriauciunas KM; Goldstein BJ; Lipes MA; Kahn CR
    J Cell Physiol; 1993 Mar; 154(3):486-95. PubMed ID: 8382208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
    Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
    Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
    Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
    J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of human thymocytes after infection by EBV.
    Paterson RL; Kelleher CA; Streib JE; Amankonah TD; Xu JW; Jones JF; Gelfand EW
    J Immunol; 1995 Feb; 154(3):1440-9. PubMed ID: 7822809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
    Fischer E; Appay MD; Cook J; Kazatchkine MD
    J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
    Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
    Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus infection of rat lymphocytes expressing human CD21 results in restricted latent viral gene expression and not in immunoblastic transformation.
    Yang L; Ikeda H; Lai Y; Yoshiki T; Takada K
    J Med Virol; 2003 May; 70(1):126-30. PubMed ID: 12629653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CR2 ligands modulate human B cell activation.
    Bohnsack JF; Cooper NR
    J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.